-- PAS002 is a proprietary DNA tolerizing vaccine construct encoding GlialCAM ---- PAS002 effectively reduces disease severity, delays onset of...
Menlo Park, California, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today...
• UB-612 Phase 3 COVID-19 Heterologous Boost Trial on Track for Topline Readout in Fourth Quarter of 2022 • UB-312...
- Transition to transient transfection-based manufacturing process continues for SGT-001; Company expects to continue dosing patients in 2023 - -...
- Following the recent submission of the IND application for CNTY-101 and pending FDA clearance, the Phase 1 ELiPSE-1 trial...
Advancement across Company’s pipeline towards regulatory and data milestonesBOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA,...
Better Choice Reports Record Second Quarter 2022 Gross Sales of $19.8 Million and Net Sales of $16.5 Million, Representing a...
Disposition of MPS programs allows Abeona to extend runway of current cash into 2Q 2023 Phase 3 VIITAL™ study topline...
Verrica held Type A meeting with the FDA regarding the path forward for the resubmission and potential approval of the...
NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Innovation1 Biotech Inc. (OTCQB: IVBT) (“Innovation1” or the “Company”), a small molecule...
WVE-006 announced as investigational development candidate for AATD with CTA submissions expected in 2023; first-in-class RNA editing candidate and most advanced...
BALTIMORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative...
VANCOUVER, British Columbia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQX: DOCRF, Frankfurt: 6PH)...
Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc....
31% increase in branded cannabis net revenue1 to $10.0 million from $7.6 million in the prior year#12 ranking for market...
WEBCASTED PRESENTATION TO BE HELD WEDNESDAY, AUGUST 17THCINCINNATI, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company” or “Quipt”)...
– Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid...
- Topline Data Expected First Quarter 2023 -DUBLIN, Ireland and FORT WASHINGTON, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Nabriva...
Lucira COVID-19 & Flu Test – the 99% Accurate At-Home Test for Covid and Flu The first and only at-home...
-- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data...